BioCentury | Oct 28, 2020
Distillery Therapeutics

Inhibiting IL-33-driven inflammation to treat brain cancer

...tumor burden and prolonged survival. Next steps include developing compounds that inhibit nuclear activity by IL-33.AnaptysBio Inc....
BioCentury | Oct 15, 2020
Product Development

Oct. 14 Quick Takes: FDA approves first Ebola therapy; plus Vertex tumbles after hours on AAT discontinuation

...to treat myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia after failure of azacitidine, decitabine or both. AnaptysBio...
BioCentury | Aug 1, 2020
Management Tracks

Nabel leaves Moderna’s board to avoid conflict-of-interest concerns; plus changes at Genespire, La Jolla, Editas and more

...was CEO. La Jolla’s previous principal executive, CFO Dennis Mulroy, departed in May. Mulroy joined AnaptysBio Inc....
...BioCentury Staff Moderna Inc. Genespire Inc. La Jolla Pharmaceutical Co. Editas Medicine Inc. Arcutis Biotherapeutics Inc. Veracyte Inc. Merus N.V. Evolve BioSystems Inc. Agendia Mindera Corp. AnaptysBio Inc....
BioCentury | Jul 18, 2020
Management Tracks

Genzyme vet Modur joins Zikani; plus Scholar Rock, Poseida, Ribon, Kiadis and more

...licensed exclusive, worldwide rights to an NK cell therapy from Kiadis. Inflammation and oncology company AnaptysBio Inc....
...Inc. Ribon Therapeutics Inc. Innate Pharma S.A. Kiadis Pharma N.V. Zikani Therapeutics Inc. Tarsus Pharmaceuticals Inc. MaaT Pharma S.A. Neurogene Poseida Therapeutics Inc. Poseida Therapeutics AnaptysBio Inc. Scholar...
BioCentury | Jun 18, 2020
Emerging Company Profile

Lassen emerges from Frazier with over $31M and a mAb for fibrosis and cancer

...fellow co-founder David King, the company’s CSO. King held the same position at antibody company AnaptysBio Inc....
BioCentury | Apr 10, 2020
Management Tracks

Shakeup at Arix; plus Emergent, AlloVir, Asklepios Bio, Morphic, Gritstone and more

...position at the gamma delta immunotherapy company. He was CMO and chief development officer of AnaptysBio Inc....
BioCentury | Jan 31, 2020
Distillery Therapeutics

TNFR2 and IL-33 identified as targets in Dupuytren's disease

...cells than immune cells, with myofibroblasts secreting 60% of the total IL-33 in the nodules. AnaptysBio Inc....
BioCentury | Jan 10, 2020
Company News

Lilly bolsters atopic dermatitis arsenal via $1.1B Dermira deal, gaining Dupixent challenger

...February. The mechanism of targeting IL-33 for atopic dermatitis took a hit in November after AnaptysBio Inc....
...etokimab missed the primary endpoint in a Phase IIb trial to treat atopic dermatitis (see “AnaptysBio...
BioCentury | Nov 8, 2019
Clinical News

AnaptysBio left with slimmer pipeline after eczema candidate fails Phase IIb

...that includes one ongoing study of etokimab and one candidate to treat autoimmune blistering disorders. AnaptysBio Inc....
...Eczema Area and Severity Index compared with placebo at week 16. The news drove down AnaptysBio's...
...LSE:GSK; NYSE:GSK) has exclusive rights to four cancer candidates from AnaptysBio under a 2014 deal. AnaptysBio...
BioCentury | Oct 19, 2019
Product Development

Tracking the rise and fall of next-generation checkpoint targets for cancer

...suppressor of T cell activation Winnie Pong, Senior Writer, Research & Analytics Bristol-Myers Squibb Co. Immutep Ltd. Roche Novartis AG GlaxoSmithKline plc AnaptysBio Inc. cCAM...
Items per page:
1 - 10 of 111
BioCentury | Oct 28, 2020
Distillery Therapeutics

Inhibiting IL-33-driven inflammation to treat brain cancer

...tumor burden and prolonged survival. Next steps include developing compounds that inhibit nuclear activity by IL-33.AnaptysBio Inc....
BioCentury | Oct 15, 2020
Product Development

Oct. 14 Quick Takes: FDA approves first Ebola therapy; plus Vertex tumbles after hours on AAT discontinuation

...to treat myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia after failure of azacitidine, decitabine or both. AnaptysBio...
BioCentury | Aug 1, 2020
Management Tracks

Nabel leaves Moderna’s board to avoid conflict-of-interest concerns; plus changes at Genespire, La Jolla, Editas and more

...was CEO. La Jolla’s previous principal executive, CFO Dennis Mulroy, departed in May. Mulroy joined AnaptysBio Inc....
...BioCentury Staff Moderna Inc. Genespire Inc. La Jolla Pharmaceutical Co. Editas Medicine Inc. Arcutis Biotherapeutics Inc. Veracyte Inc. Merus N.V. Evolve BioSystems Inc. Agendia Mindera Corp. AnaptysBio Inc....
BioCentury | Jul 18, 2020
Management Tracks

Genzyme vet Modur joins Zikani; plus Scholar Rock, Poseida, Ribon, Kiadis and more

...licensed exclusive, worldwide rights to an NK cell therapy from Kiadis. Inflammation and oncology company AnaptysBio Inc....
...Inc. Ribon Therapeutics Inc. Innate Pharma S.A. Kiadis Pharma N.V. Zikani Therapeutics Inc. Tarsus Pharmaceuticals Inc. MaaT Pharma S.A. Neurogene Poseida Therapeutics Inc. Poseida Therapeutics AnaptysBio Inc. Scholar...
BioCentury | Jun 18, 2020
Emerging Company Profile

Lassen emerges from Frazier with over $31M and a mAb for fibrosis and cancer

...fellow co-founder David King, the company’s CSO. King held the same position at antibody company AnaptysBio Inc....
BioCentury | Apr 10, 2020
Management Tracks

Shakeup at Arix; plus Emergent, AlloVir, Asklepios Bio, Morphic, Gritstone and more

...position at the gamma delta immunotherapy company. He was CMO and chief development officer of AnaptysBio Inc....
BioCentury | Jan 31, 2020
Distillery Therapeutics

TNFR2 and IL-33 identified as targets in Dupuytren's disease

...cells than immune cells, with myofibroblasts secreting 60% of the total IL-33 in the nodules. AnaptysBio Inc....
BioCentury | Jan 10, 2020
Company News

Lilly bolsters atopic dermatitis arsenal via $1.1B Dermira deal, gaining Dupixent challenger

...February. The mechanism of targeting IL-33 for atopic dermatitis took a hit in November after AnaptysBio Inc....
...etokimab missed the primary endpoint in a Phase IIb trial to treat atopic dermatitis (see “AnaptysBio...
BioCentury | Nov 8, 2019
Clinical News

AnaptysBio left with slimmer pipeline after eczema candidate fails Phase IIb

...that includes one ongoing study of etokimab and one candidate to treat autoimmune blistering disorders. AnaptysBio Inc....
...Eczema Area and Severity Index compared with placebo at week 16. The news drove down AnaptysBio's...
...LSE:GSK; NYSE:GSK) has exclusive rights to four cancer candidates from AnaptysBio under a 2014 deal. AnaptysBio...
BioCentury | Oct 19, 2019
Product Development

Tracking the rise and fall of next-generation checkpoint targets for cancer

...suppressor of T cell activation Winnie Pong, Senior Writer, Research & Analytics Bristol-Myers Squibb Co. Immutep Ltd. Roche Novartis AG GlaxoSmithKline plc AnaptysBio Inc. cCAM...
Items per page:
1 - 10 of 111